Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonalimab with chemotherapy as neoadjuvant treatment for locally advanced cervical cancer (phase II)
ChiCTR2600118183Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of iparomlimab and tuvonalimab in Cervical Cancer (CC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Pathological complete remission rate and Objective remission rate. Started Feb 2026; status: recruiting.
02
Drugs
iparomlimabtuvonalimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600118183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118183.